Home › Diffuse Scleroderma › North Carolina › Durham
Diffuse Scleroderma clinical trials in Durham, NC
6 studies for Diffuse Scleroderma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- Duke University Medical Center, Durham
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPhase 1
- University of North Carolina TraCS Institute - CTRC, Chapel Hill · 10 mi away
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- Duke University Medical Center, Durham
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
- Duke University, Durham
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
- Duke University, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RecruitingObservational studyHealthy volunteers welcome
- Duke University, Durham
Diffuse Scleroderma trials in other cities
- New York City, NY8 studies
- Chicago, IL7 studies
- Ann Arbor, MI7 studies
- Los Angeles, CA6 studies
- Baltimore, MD5 studies
- Houston, TX5 studies
- Boston, MA5 studies
- Kansas City, KS4 studies
- Philadelphia, PA4 studies
- New Orleans, LA4 studies
- Pittsburgh, PA4 studies
- Charleston, SC3 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)59 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Metastatic Cancer33 studies
- Acute Myeloid Leukemia33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Ovarian Cancer27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.